Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Signe HässlerDelphine BacheletJulianne DuhazeNatacha SzelyAude GleizesSalima Hacein-Bey AbinaOrhan AktasMichael AuerJerome AvouacMary BirchlerYoram BouhnikOlivier BrocqDorothea Buck-MartinGuillaume CadiotFranck CarbonnelYehuda ChowersManuel Comabella LopezTobias DerfussNiek De VriesNaoimh DonnellanAbiba DoukaniMichael GugerHans-Peter HartungEva Kubala HavrdováBernhard HemmerTom HuizingaKathleen IngenhovenPoul Erik Hyldgaard-JensenElizabeth C JuryMicheal KhalilBernd KieseierAnna LaurénRaija Lp LindbergAmy LoercherEnrico MaggiJessica MansonClaudia MauriBadreddine Mohand OumoussaXavier MontalbanMaria NachuryPetra NytrovaChristophe RichezMalin RynerFinn SellebjergClaudia SieversDan SikkemaMartin SoubrierSophie TourdotCaroline Trang-PoissonAlessandra VultaggioClemens WarnkeSebastian SpindeldreherPierre DönnesTimothy P HicklingAgnès Hincelin MeryMatthieu AllezFlorian DeisenhammerAnna Fogdell-HahnXavier MarietteMarc PallardyPhilippe Broëtnull nullPublished in: PLoS medicine (2020)
In our study, we found that immunosuppressants and antibiotics were associated with decreased risk of ADA development, whereas tobacco smoking and infections during the study were associated with increased risk. We found that the HLA-DQA1*05 allele was associated with an increased rate of immunogenicity. Moreover, our results suggest a relationship between CXCL12 production and ADA development independent of the disease, which is consistent with its known function in affinity maturation of antibodies and plasma cell survival. Our findings may help physicians in the management of patients receiving biotherapies.
Keyphrases